About acadia pharmaceuticals inc. - ACAD
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
ACAD At a Glance
ACADIA Pharmaceuticals, Inc.
12830 El Camino Real
San Diego, California 92130-3331
| Phone | 1-858-558-2871 | Revenue | 1.07B | |
| Industry | Pharmaceuticals: Major | Net Income | 391.00M | |
| Sector | Health Technology | 2025 Sales Growth | 11.872% | |
| Fiscal Year-end | 12 / 2026 | Employees | 798 | |
| View SEC Filings |
ACAD Valuation
| P/E Current | 9.33 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 11.607 |
| Price to Sales Ratio | 4.236 |
| Price to Book Ratio | 3.706 |
| Price to Cash Flow Ratio | 41.32 |
| Enterprise Value to EBITDA | 32.35 |
| Enterprise Value to Sales | 3.519 |
| Total Debt to Enterprise Value | 0.014 |
ACAD Efficiency
| Revenue/Employee | 1,342,738.095 |
| Income Per Employee | 489,974.937 |
| Receivables Turnover | 7.229 |
| Total Asset Turnover | 0.779 |
ACAD Liquidity
| Current Ratio | 3.833 |
| Quick Ratio | 3.708 |
| Cash Ratio | 2.958 |
ACAD Profitability
| Gross Margin | 90.678 |
| Operating Margin | 9.782 |
| Pretax Margin | 12.963 |
| Net Margin | 36.491 |
| Return on Assets | 28.416 |
| Return on Equity | 39.894 |
| Return on Total Capital | 30.557 |
| Return on Invested Capital | 38.281 |
ACAD Capital Structure
| Total Debt to Total Equity | 4.252 |
| Total Debt to Total Capital | 4.078 |
| Total Debt to Total Assets | 3.336 |
| Long-Term Debt to Equity | 3.304 |
| Long-Term Debt to Total Capital | 3.169 |